|Mr. Antony Mattessich||Pres, CEO & Director||1.04M||N/A||1967|
|Mr. Donald Notman Jr.||Chief Financial Officer||629.17k||N/A||N/A|
|Dr. Michael H. Goldstein M.B.A., M.D., M.M.||Chief Strategy Advisor||735.75k||N/A||1967|
|Dr. Peter K. Jarrett Ph.D.||Chief Scientific Officer||N/A||N/A||1957|
|Mr. Philip C. Strassburger||Gen. Counsel||N/A||N/A||1960|
|Mr. William H. Ransone II||VP of Global Sales & Marketing||N/A||N/A||N/A|
|Ms. Tracy Smith||VP of HR||N/A||N/A||N/A|
|Mr. Scott Corning||Sr. VP of Commercial||N/A||N/A||N/A|
|Mr. Christopher G. White||Chief Bus. Officer||N/A||N/A||1962|
|Dr. Rabia Gurses Ozden M.D.||Chief Medical Officer||N/A||N/A||1968|
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Ocular Therapeutix, Inc.’s ISS governance QualityScore as of 31 July 2022 is 8. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 7; Compensation: 8.